Warfarin Treatment and All‐Cause Mortality in Community‐Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study
Authors:
- Alberto PilottoAPAlberto Pilotto
- Massimiliano CopettiMCMassimiliano Copetti
- Andrea PilottoAPAndrea Pilotto
- Francesco PanzaFrancesco Panza
- the Multidimensional Prognostic Index_Age Project InvestigatorsTIthe Multidimensional Prognostic Index_Age Project Investigators
- 13 June 2016
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 64 (7) , 1416-1424
Abstract
Objectives: To investigate the relationship between warfarin treatment and different strata of all‐cause mortality risk assessed using the Multidimensional Prognostic Index ( MPI ) based on information collected using the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) in community‐dwelling older adults with atrial fibrillation ( AF ). Design: Retrospective observational study. Setting: Older community‐dwelling adults who underwent a SV a MA evaluation establishing accessibility to homecare services and nursing home admission from 2005 to 2013 in the Padova Health District, Italy. Participants: Community‐dwelling individuals with AF aged 65 and older (N = 1,827). Measurements: Participants were classified as being at mild ( MPI ‐ SV a MA ‐1), moderate ( MPI ‐ SV a MA ‐2), or severe ( MPI ‐ SV a MA ‐3) risk of mortality using the MPI ‐ SV a MA , a validated prognostic tool based on age, sex, comorbidity, cognitive status, mobility and functional disability, pressure sore risk, and social support. The association between warfarin treatment and mortality was tested using multivariate‐ and propensity score–adjusted Cox regression models, controlling for age, sex, all SV a MA domains, concomitant diseases, and drug treatments. Results: Higher MPI ‐ SV a MA scores were associated with lower rates of warfarin treatment and higher 3‐year mortality. After adjustment for propensity score quintiles, warfarin treatment was significantly associated with lower 2‐year mortality in individuals with MPI ‐ SV a MA ‐1 (hazard ratio ( HR ) = 0.64, 95% confidence interval ( CI ) = 0.50–0.82), MPI ‐ SV a MA ‐2 ( HR = 0.68, 95% CI = 0.55–0.85), and MPI ‐ SV a MA ‐3 ( HR = 0.55, 95% CI = 0.44–0.67). Heterogeneity analyses confirmed that the effect of warfarin treatment was not different between MPI ‐ SV a MA groups ( P for heterogeneity = .48). Conclusion: Community‐dwelling older adults with AF benefitted from anticoagulation in terms of lower all‐cause mortality over a mean follow‐up of 2 years, regardless of poor health and functional condition. Although this benefit can be ascribed to the treatment, it may also reflect better overall care.Keywords
Funding Information
- MPI_Age European project
- Health and Consumers of the European Innovation Partnership on Active
- Healthy Ageing Second Health Programme
This publication has 47 references indexed in Scilit:
- The use of anticoagulants in the management of atrial fibrillation among general practices in EnglandHeart, 2013
- Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009Heart, 2012
- Comparing the Prognostic Accuracy for All-Cause Mortality of Frailty Instruments: A Multicentre 1-Year Follow-Up in Hospitalized Older PatientsPLOS ONE, 2012
- The Central Role of Prognosis in Clinical Decision MakingJAMA, 2012
- Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillationHeart, 2011
- Practice-Level Variation in Warfarin Use Among Outpatients With Atrial Fibrillation (from the NCDR PINNACLE Program)The American Journal of Cardiology, 2011
- The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillationAge and Ageing, 2008
- Development and Validation of a Multidimensional Prognostic Index for One-Year Mortality from Comprehensive Geriatric Assessment in Hospitalized Older PatientsRejuvenation Research, 2008
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004